$SSKN
STRATA Skin Sciences, Inc.

2024 Q2 Form 10-Q Financial Statement

#000114036124026260 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $8.435M $6.754M $7.567M
YoY Change 2.24% -10.74% 7.47%
Cost Of Revenue $3.498M $3.674M $3.179M
YoY Change -11.04% 15.57% 9.13%
Gross Profit $4.937M $3.080M $4.388M
YoY Change 14.34% -29.81% 6.3%
Gross Profit Margin 58.53% 45.6% 57.99%
Selling, General & Admin $5.224M $5.728M $6.659M
YoY Change -11.55% -13.98% 6.24%
% of Gross Profit 105.81% 185.97% 151.75%
Research & Development $199.0K $241.0K $315.0K
YoY Change -46.79% -23.49% 93.25%
% of Gross Profit 4.03% 7.82% 7.18%
Depreciation & Amortization $1.250M $1.249M $677.0K
YoY Change -12.46% 84.49% 8.32%
% of Gross Profit 25.32% 40.55% 15.43%
Operating Expenses $5.423M $5.969M $6.974M
YoY Change -13.65% -14.41% 8.44%
Operating Profit -$486.0K -$2.889M -$2.586M
YoY Change -75.23% 11.72% 12.29%
Interest Expense -$477.0K $524.0K $286.0K
YoY Change -260.07% 83.22% 43.72%
% of Operating Profit
Other Income/Expense, Net $387.0K -$479.0K -$249.0K
YoY Change -132.63% 92.37% 25.13%
Pretax Income -$99.00K -$3.368M -$2.835M
YoY Change -96.86% 18.8% 13.31%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$99.00K -$3.368M -$2.835M
YoY Change -96.86% 18.8% 13.31%
Net Earnings / Revenue -1.17% -49.87% -37.47%
Basic Earnings Per Share -$0.03 -$0.10 -$0.08
Diluted Earnings Per Share -$0.03 -$0.10 -$0.08
COMMON SHARES
Basic Shares Outstanding 35.06M 35.06M 34.88M
Diluted Shares Outstanding 3.506M 35.06M 34.86M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.483M $5.237M $2.825M
YoY Change -39.31% 85.38% -74.14%
Cash & Equivalents $5.483M $5.237M $2.825M
Short-Term Investments
Other Short-Term Assets $1.671M $1.677M $2.052M
YoY Change -11.54% -18.27% 422.14%
Inventory $2.692M $2.695M $5.695M
Prepaid Expenses
Receivables $3.979M $3.630M $3.940M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $13.83M $13.24M $14.51M
YoY Change -34.93% -8.77% -23.81%
LONG-TERM ASSETS
Property, Plant & Equipment $11.15M $11.73M $8.182M
YoY Change 34.02% 43.31% 18.22%
Goodwill $6.519M $6.519M $8.803M
YoY Change -25.95% -25.95%
Intangibles $6.334M $6.825M $16.67M
YoY Change -60.31% -59.07%
Long-Term Investments
YoY Change
Other Assets $325.0K $231.0K $82.00K
YoY Change 357.75% 181.71% -59.0%
Total Long-Term Assets $25.76M $26.81M $34.61M
YoY Change -24.16% -22.54% -3.97%
TOTAL ASSETS
Total Short-Term Assets $13.83M $13.24M $14.51M
Total Long-Term Assets $25.76M $26.81M $34.61M
Total Assets $39.58M $40.05M $49.12M
YoY Change -28.3% -18.47% -10.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.886M $3.592M $3.099M
YoY Change -25.62% 15.91% -21.94%
Accrued Expenses $6.608M $6.269M $6.549M
YoY Change -1.83% -4.28% 0.15%
Deferred Revenue $2.261M $2.366M $2.548M
YoY Change -7.18% -7.14% -18.36%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.13M $12.59M $13.06M
YoY Change -14.07% -3.6% -9.44%
LONG-TERM LIABILITIES
Long-Term Debt $15.11M $15.08M $7.517M
YoY Change 0.85% 100.55% 2.19%
Other Long-Term Liabilities $2.652M $2.767M $8.921M
YoY Change -70.14% -68.98% -3.72%
Total Long-Term Liabilities $15.11M $15.08M $7.517M
YoY Change 0.85% 100.55% -54.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.13M $12.59M $13.06M
Total Long-Term Liabilities $15.11M $15.08M $7.517M
Total Liabilities $30.09M $30.62M $29.80M
YoY Change -21.44% 2.73% -4.81%
SHAREHOLDERS EQUITY
Retained Earnings -$241.5M -$241.4M -$230.1M
YoY Change 3.57% 4.94%
Common Stock $4.000K $35.00K $35.00K
YoY Change -88.57% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.496M $9.432M $19.32M
YoY Change
Total Liabilities & Shareholders Equity $39.58M $40.05M $49.12M
YoY Change -28.3% -18.47% -10.83%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$99.00K -$3.368M -$2.835M
YoY Change -96.86% 18.8% 13.31%
Depreciation, Depletion And Amortization $1.250M $1.249M $677.0K
YoY Change -12.46% 84.49% 8.32%
Cash From Operating Activities $591.0K -$804.0K -$1.203M
YoY Change 237.71% -33.17% 240.79%
INVESTING ACTIVITIES
Capital Expenditures $345.0K $725.0K $1.406M
YoY Change -62.94% -48.44% -307.07%
Acquisitions $0.00
YoY Change -100.0%
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$345.0K -$725.0K -$1.406M
YoY Change -62.94% -48.44% 7.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -18.00K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 591.0K -804.0K -1.203M
Cash From Investing Activities -345.0K -725.0K -1.406M
Cash From Financing Activities 0.000 -18.00K 0.000
Net Change In Cash 246.0K -1.547M -2.609M
YoY Change -96.04% -40.71% 56.89%
FREE CASH FLOW
Cash From Operating Activities $591.0K -$804.0K -$1.203M
Capital Expenditures $345.0K $725.0K $1.406M
Free Cash Flow $246.0K -$1.529M -$2.609M
YoY Change -132.54% -41.4% -900.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001051514
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6754000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7567000
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
3674000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
3179000
CY2024Q1 us-gaap Gross Profit
GrossProfit
3080000
CY2023Q1 us-gaap Gross Profit
GrossProfit
4388000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
241000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
315000
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3018000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3742000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2710000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2917000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
5969000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
6974000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2889000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2586000
CY2024Q1 us-gaap Interest Expense
InterestExpense
524000
CY2023Q1 us-gaap Interest Expense
InterestExpense
286000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
45000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-479000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-249000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3368000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2835000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35060920
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35060920
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34862092
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34862092
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12688000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
112000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3368000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
9432000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21831000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
325000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2835000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
19321000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3368000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2835000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1249000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1397000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
95000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
105000
CY2024Q1 sskn Amortization Of Debt Issuance Costs And Debt Discount Premium
AmortizationOfDebtIssuanceCostsAndDebtDiscountPremium
31000
CY2023Q1 sskn Amortization Of Debt Issuance Costs And Debt Discount Premium
AmortizationOfDebtIssuanceCostsAndDebtDiscountPremium
41000
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
84000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-95000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
112000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
325000
CY2024Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-13000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
141000
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-726000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-626000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
154000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-283000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
31000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
261000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-326000
CY2024Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-57000
CY2023Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-12000
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
194000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-247000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-100000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-95000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-804000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-817000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
725000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1792000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-725000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1792000
CY2024Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
18000
CY2023Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-18000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1547000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2609000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8118000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6795000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6571000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4186000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5237000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2825000
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
1334000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
1361000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6571000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4186000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
480000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
241000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
977000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2024Q1 sskn Transfer Of Property And Equipment To Inventories
TransferOfPropertyAndEquipmentToInventories
9000
CY2023Q1 sskn Transfer Of Property And Equipment To Inventories
TransferOfPropertyAndEquipmentToInventories
45000
CY2024Q1 sskn Accrued Payment Of Contingent Consideration
AccruedPaymentOfContingentConsideration
6000
CY2023Q1 sskn Accrued Payment Of Contingent Consideration
AccruedPaymentOfContingentConsideration
14000
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Reclassifications</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Certain prior year amounts have been reclassified to conform to the current year presentation, including the impact on the condensed consolidated statement of cash flows of the reclassification of lasers-in-process from inventories to property and equipment, net.</div>
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div> <div style="text-align: justify; font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Use of Estimates</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; font-style: normal;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company’s significant estimates and judgments include revenue recognition with respect to deferred revenues and the contract term and valuation allowances of accounts receivable, inputs used when evaluating goodwill for impairment, inputs used in the valuation of contingent consideration, state sales and use tax accruals, the estimated useful lives of intangible assets, and the valuation allowance related to deferred tax assets. Actual results could differ from those estimates.</div>
CY2023Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
303000
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
207000
CY2024Q1 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
39000
CY2023Q1 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
27000
CY2024Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
64000
CY2023Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
5000
CY2024Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
278000
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
229000
CY2024Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
175000
CY2023Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
152000
CY2024Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
103000
CY2023Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
77000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
377000
CY2024Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
76000
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
132000
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6213723
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4957937
CY2024Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P36M
CY2024Q1 us-gaap Lessee Finance Lease Renewal Term1
LesseeFinanceLeaseRenewalTerm1
P1Y
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
628000
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
251000
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q1 sskn Contract With Customer Liability Current Advance Consideration
ContractWithCustomerLiabilityCurrentAdvanceConsideration
251000
CY2024Q1 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2421000
CY2023Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2192000
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
274000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
481000
CY2024Q1 us-gaap Inventory Net
InventoryNet
2695000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2673000
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
141000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36743000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36062000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25017000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24284000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11726000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11778000
CY2024Q1 us-gaap Depreciation
Depreciation
755000
CY2023Q1 us-gaap Depreciation
Depreciation
677000
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24222000
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
17397000
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6825000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24222000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16903000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7319000
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
494000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
720000
CY2024Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1477000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1266000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
561000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
561000
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
561000
CY2024Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
175000
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
180000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1667000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1679000
CY2024Q1 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
4290000
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
4316000
CY2024Q1 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
137000
CY2023Q4 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
131000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6269000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6306000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3750000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
7500000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
3750000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
15000000
CY2024Q1 sskn Debt Instrument Exit Fee
DebtInstrumentExitFee
600000
CY2024Q1 sskn Long Term Debt After Exit Fee
LongTermDebtAfterExitFee
15600000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
525000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15075000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6754000
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
3674000
CY2024Q1 us-gaap Gross Profit
GrossProfit
3080000
CY2024Q1 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.456
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
241000
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3018000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2710000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
5969000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2889000
CY2024Q1 us-gaap Interest Expense
InterestExpense
524000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
45000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3368000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7567000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
3179000
CY2023Q1 us-gaap Gross Profit
GrossProfit
4388000
CY2023Q1 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.58
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
315000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3742000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2917000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
6974000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2586000
CY2023Q1 us-gaap Interest Expense
InterestExpense
286000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2835000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1249000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1397000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6754000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7567000
CY2024Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2024Q1 sskn Change In Operating Lease Right Of Use Assets And Liability Due To Amended Lease
ChangeInOperatingLeaseRightOfUseAssetsAndLiabilityDueToAmendedLease
977000
CY2023Q1 sskn Change In Operating Lease Right Of Use Assets And Liability Due To Amended Lease
ChangeInOperatingLeaseRightOfUseAssetsAndLiabilityDueToAmendedLease
0
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
106000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
106000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
112000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
96000
CY2024Q1 sskn Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.1194
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
341000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
463000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
334000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
290000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
301000
CY2024Q1 sskn Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
231000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1960000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
494000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1466000
CY2024Q1 sskn Development Agreement Term
DevelopmentAgreementTerm
P3Y
CY2023Q1 sskn Litigation Settlement To Be Paid
LitigationSettlementToBePaid
106000
CY2024Q1 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
106000
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001140361-24-026260-index-headers.html Edgar Link pending
0001140361-24-026260-index.html Edgar Link pending
0001140361-24-026260.txt Edgar Link pending
0001140361-24-026260-xbrl.zip Edgar Link pending
ef20026312_10q.htm Edgar Link pending
ef20026312_ex31-1.htm Edgar Link pending
ef20026312_ex31-2.htm Edgar Link pending
ef20026312_ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ef20026312_10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sskn-20240331.xsd Edgar Link pending
sskn-20240331_def.xml Edgar Link unprocessable
sskn-20240331_lab.xml Edgar Link unprocessable
sskn-20240331_pre.xml Edgar Link unprocessable
sskn-20240331_cal.xml Edgar Link unprocessable